INTRODUCTION: A 27-year-old female patient with known tuberous sclerosis complex (TSC), polycystic kidneys with multiple large bilateral angiomyolipomas, and failing renal functions with prehemodialysis values (urea: 19 mmol/L; creatinine: 317 μmol/L; CKD-EPI 0,27) was admitted to our department for pre-renal transplant evaluation. The patient was placed on the transplant waiting list as the living donor did not pass pretransplant workup and was subsequently contraindicated. Patient was placed on the "cadaverous kidney transplant waiting list". METHOD: Computed tomography angiography revealed symptomatic PSA in the right kidney angiomyolipoma (AML). The patient underwent urgent transarterial embolisation of the PSA's feeding vessel in the right kidney AML. Based on the "kidney transplant waiting list" order patient underwent a bilateral nephrectomy combined with transperitoneal renal allotransplantation of a cadaverous kidney graft through midline laparotomy, appendectomy, and cholecystectomy. RESULTS: Postoperative period was complicated by delayed graft function caused by acute tubular necrosis requiring postoperative hemodialysis. The patient was discharged on the 17th postoperative day with a good renal graft function. Patient's follow-up is currently 23 months with good graft function (urea: 9 mmol/L; creatinine: 100 μmol/L). CONCLUSION: Renal transplantation combined with radical nephrectomy provides a definitive treatment for TSC renal manifestations.

1st Faculty of Medicine Charles University Prague Czech Republic

2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Surgery Department Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Hong C., Tu H., Lin J., Lee C. An estimation of the incidence of tuberous sclerosis complex in a nationwide retrospective cohort study (1997-2010) British Journal of Dermatology. 2016;174(6):1282–1289. doi: 10.1111/bjd.14415. PubMed DOI

Wataya-Kaneda M., Uemura M., Fujita K., et al. Tuberous sclerosis complex: Recent advances in manifestations and therapy. International Journal of Urology. 2017;24(9):681–691. doi: 10.1111/iju.13390. PubMed DOI

Cockerell I., Guenin M., Heimdal K., Bjørnvold M., Selmer K. K., Rouvière O. Renal manifestations of tuberous sclerosis complex: patients’ and parents’ knowledge and routines for renal follow-up – a questionnaire study. BMC Nephrology. 2018;19, article 39 doi: 10.1186/s12882-018-0835-3. PubMed DOI PMC

Amin S., Lux A., Calder N., Laugharne M., Osborne J., O'callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Developmental Medicine & Child Neurology. 2017;59(6):612–617. doi: 10.1111/dmcn.13352. PubMed DOI

Rabenou R. A., Charles H. W. Differentiation of sporadic versus tuberous sclerosis complex–associated angiomyolipoma. American Journal of Roentgenology. 2015;205(2):292–301. doi: 10.2214/AJR.14.14255. PubMed DOI

Sasaki H., Iwami D., Hotta K., Morita K., Naka T., Shinohara N. Spontaneous reduction of native kidney size involving angiomyolipoma lesions in a kidney transplant recipient with tuberous sclerosis complex. International Journal of Urology. 2018;25(5):513–514. doi: 10.1111/iju.13534. PubMed DOI

Lim C. C., Tan H., Thangaraju S., Lai A. H., Foo M. W. End-stage renal disease in tuberous sclerosis complex-polycystic kidney disease contiguous gene syndrome: epidemiology, clinical manifestations and implications for transplantation. International Urology and Nephrology. 2014;46(9):1869–1870. doi: 10.1007/s11255-014-0735-9. PubMed DOI

Ramaswamy R. S., Akinwande O., Tiwari T. Renal embolization: current recommendations and rationale for clinical practice. Current Urology Reports. 2018;19(3, article 5) doi: 10.1007/s11934-018-0756-5. PubMed DOI

Sawada Y., Shimohira M., Hashizume T., et al. Transcatheter arterial embolization for renal angiomyolipoma using a micro-balloon catheter and a mixture of ethanol and lipiodol. CardioVascular and Interventional Radiology. 2017;40(12):1933–1939. doi: 10.1007/s00270-017-1731-0. PubMed DOI

Dallos G., Chmel R., Alföldy F., et al. Bourneville-pringle disease for kidney transplantation: a single-center experience. Transplantation Proceedings. 2006;38(9):2823–2824. doi: 10.1016/j.transproceed.2006.08.121. PubMed DOI

Bissler J. J., Kingswood J. C., Radzikowska E., et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8) doi: 10.1371/journal.pone.0180939.e0180939 PubMed DOI PMC

Curatolo P., Moavero R. mTOR inhibitors in tuberous sclerosis complex. Current Neuropharmacology. 2012;10(4):404–415. doi: 10.2174/157015912804143595. PubMed DOI PMC

Bissler J. J., Kingswood J. C., Radzikowska E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2013;381(9869):817–824. doi: 10.1016/s0140-67361261767-x. PubMed DOI

Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M., et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet. 2010;375:2073–2081. doi: 10.1016/s0140-6736(10)60674-5. PubMed DOI PMC

Bissler J. J., Nonomura N., Budde K., et al. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis. PLoS ONE. 2018;13(9) doi: 10.1371/journal.pone.0201005.e0201005 PubMed DOI PMC

Sun P., Liu J., Charles H., Hulbert J., Bissler J. Outcomes of angioembolization and nephrectomy for renal angiomyolipoma associated with tuberous sclerosis complex: a real-world US national study. Current Medical Research and Opinion. 2017;33(5):821–827. doi: 10.1080/03007995.2017.1286307. PubMed DOI

Varga M., Kudla M., Vargova L., Fronek J. Cholecystectomy for acute cholecystitis after renal transplantation. Transplantation Proceedings. 2016;48(6):2072–2075. doi: 10.1016/j.transproceed.2016.02.079. PubMed DOI

Gupta N., Henske E. P. Pulmonary manifestations in tuberous sclerosis complex. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2018;178(3):326–337. doi: 10.1002/ajmg.c.31638. PubMed DOI PMC

Bissler J. J., McCormack F. X., Young L. R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. The New England Journal of Medicine. 2008;358(2):140–151. doi: 10.1056/nejmoa063564. PubMed DOI PMC

McCormack F. X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England Journal of Medicine. 2011;364(17):1595–1606. doi: 10.1056/NEJMoa1100391. PubMed DOI PMC

Takada T., Mikami A., Kitamura N., et al. Efficacy and safety of long-term sirolimus therapy for asian patients with lymphangioleiomyomatosis. Annals of the American Thoracic Society. 2016;13(11):1912–1922. doi: 10.1513/AnnalsATS.201605-335OC. PubMed DOI

Goldberg H. J., Harari S., Cottin V., et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. European Respiratory Journal. 2015;46(3):783–794. doi: 10.1183/09031936.00210714. PubMed DOI